101
|
Waters B, Sample A, Smith J, Bonde P. Toward total implantability using free-range resonant electrical energy delivery system: achieving untethered ventricular assist device operation over large distances. Cardiol Clin 2011; 29:609-25. [PMID: 22062212 DOI: 10.1016/j.ccl.2011.08.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Heart failure is a terminal disease with a very poor prognosis. Although the gold standard of treatment remains heart transplant, only a minority of patients can benefit from transplants. Another promising alternative is mechanical circulatory assistance using ventricular assist devices. The authors envision a completely implantable cardiac assist system affording tether-free mobility in an unrestricted space powered wirelessly by the innovative Free-Range Resonant Electrical Energy Device (FREE-D) system. Patients will have no power drivelines traversing the skin, and this system will allow power to be delivered over room distances and will eliminate trouble-prone wirings, bulky consoles, and replaceable batteries.
Collapse
Affiliation(s)
- Benjamin Waters
- Department of Electrical Engineering, University of Washington, Seattle, WA 98195-2350, USA
| | | | | | | |
Collapse
|
102
|
Huttner B, Reineke T, Wilhelm MJ, Karrer U. Fatal Cytomegalovirus Pneumonitis and Ileitis in a Patient with a Cardiac Assist Device. Am Surg 2011. [DOI: 10.1177/000313481107700904] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Benedikt Huttner
- Division of Infectious Diseases University Hospital of Zurich Zurich, Switzerland
| | - Tanja Reineke
- Institute of Surgical Pathology University Hospital of Zurich Zurich, Switzerland
| | - Markus J. Wilhelm
- Clinic for Cardiovascular Surgery University Hospital of Zurich Zurich, Switzerland
| | - Urs Karrer
- Division of Infectious Diseases University Hospital of Zurich Zurich, Switerzland
| |
Collapse
|
103
|
Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, Schueler S, Holman WL, Lawler LP, Gordon SM, Mahon NG, Herre JM, Gould K, Montoya JG, Padera RF, Kormos RL, Conte JV, Mooney ML. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant 2011; 30:375-84. [PMID: 21419995 DOI: 10.1016/j.healun.2011.01.717] [Citation(s) in RCA: 267] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2011] [Accepted: 01/28/2011] [Indexed: 01/22/2023] Open
Affiliation(s)
- Margaret M Hannan
- Division of Cardiac Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
104
|
Bomholt T, Moser C, Sander K, Boesgaard S, Køber L, Olsen PS, Hansen PB, Mortensen SA, Gustafsson F. Driveline infections in patients supported with a HeartMate II: incidence, aetiology and outcome. SCAND CARDIOVASC J 2011; 45:273-8. [PMID: 21539474 DOI: 10.3109/14017431.2011.577236] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES To investigate the incidence and outcome of driveline infections in patients supported with a continuous flow left ventricular assist device (HeartMate II (HMII)) and to study the microbiological aetiology. DESIGN Retrospective analysis of 31 patients who received an implantation of a HMII. Follow-up was from implantation to either device explantation, death or closure of the study. Clinical signs of infections were divided into superficial, deep or systemic and compared to culture and gram stain, the clinical course and infectious parameters. RESULTS The incidence of driveline infections was 1.65 episodes per patient per year. Staphylococcus aureus and Escherichia coli were the most common bacterial aetiology. More than two weeks of treatment was required in 81% of the patients. In terms of detecting superficial driveline infections, leucocyte count demonstrated a sensitivity of 27% and C-reactive protein (CRP) a sensitivity of 28%. In 22 cases of driveline infections plasma pro-calcitonin was found to be normal. CONCLUSION Driveline infections are common in HMII recipients but primarily remain superficial and are reasonably easy to manage. Infectious agents mostly originate from the skin and gastrointestinal tract. Blood biomarkers did not appear to be helpful in detecting driveline infections.
Collapse
Affiliation(s)
- Tobias Bomholt
- Rigshospitalet, Department of Cardiology, University Hospital of Copenhagen, Denmark
| | | | | | | | | | | | | | | | | |
Collapse
|
105
|
Fraser KH, Taskin ME, Griffith BP, Wu ZJ. The use of computational fluid dynamics in the development of ventricular assist devices. Med Eng Phys 2011; 33:263-80. [PMID: 21075669 PMCID: PMC3053072 DOI: 10.1016/j.medengphy.2010.10.014] [Citation(s) in RCA: 147] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Revised: 10/12/2010] [Accepted: 10/15/2010] [Indexed: 02/06/2023]
Abstract
Progress in the field of prosthetic cardiovascular devices has significantly contributed to the rapid advancements in cardiac therapy during the last four decades. The concept of mechanical circulatory assistance was established with the first successful clinical use of heart-lung machines for cardiopulmonary bypass. Since then a variety of devices have been developed to replace or assist diseased components of the cardiovascular system. Ventricular assist devices (VADs) are basically mechanical pumps designed to augment or replace the function of one or more chambers of the failing heart. Computational Fluid Dynamics (CFD) is an attractive tool in the development process of VADs, allowing numerous different designs to be characterized for their functional performance virtually, for a wide range of operating conditions, without the physical device being fabricated. However, VADs operate in a flow regime which is traditionally difficult to simulate; the transitional region at the boundary of laminar and turbulent flow. Hence different methods have been used and the best approach is debatable. In addition to these fundamental fluid dynamic issues, blood consists of biological cells. Device-induced biological complications are a serious consequence of VAD use. The complications include blood damage (haemolysis, blood cell activation), thrombosis and emboli. Patients are required to take anticoagulation medication constantly which may cause bleeding. Despite many efforts blood damage models have still not been implemented satisfactorily into numerical analysis of VADs, which severely undermines the full potential of CFD. This paper reviews the current state of the art CFD for analysis of blood pumps, including a practical critical review of the studies to date, which should help device designers choose the most appropriate methods; a summary of blood damage models and the difficulties in implementing them into CFD; and current gaps in knowledge and areas for future work.
Collapse
Affiliation(s)
- Katharine H Fraser
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | | | | |
Collapse
|
106
|
Jefferson J, Whelan R, Dick B, Carling P. A Novel Technique for Identifying Opportunities to Improve Environmental Hygiene in the Operating Room. AORN J 2011; 93:358-64. [DOI: 10.1016/j.aorn.2010.08.022] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2009] [Revised: 06/22/2010] [Accepted: 08/06/2010] [Indexed: 11/17/2022]
|
107
|
Jennings DL, Chambers RM, Schillig JM. The Pharmacotherapy of the HeartMate II, a Continuous Flow Left Ventricular Assist Device, in Patients with Advanced Heart Failure: Integration of Disease, Device, and Drug. Ann Pharmacother 2010; 44:1647-50. [DOI: 10.1345/aph.1p340] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Advanced heart failure continues to be a significant cause of morbidity and mortality in the US. Patients with advanced heart failure have a poor prognosis without cardiac transplantation. The use of left ventricular assist devices (LVADs) as destination therapy for these patients is therefore expected to increase in the coming years as technology advances. The HeartMate II, a continuous flow implantable device, is currently the only LVAD that has been approved by the Food and Drug Administration for destination therapy in patients with advanced heart failure. The pharmacotherapy associated with this device is very complex and, therefore, the need for expertly trained clinical pharmacists to care for this expanding patient population wilt also likely increase. Unfortunately, most pharmacists are unfamiliar with the effect of LVADs on the physiology and pharmacotherapy of a patient's heart failure. The purpose of this article is to give clinical pharmacists an introduction to the most common pharmacotherapeutic issues for patients with LVADs and present practical solutions for managing common drug therapy problems.
Collapse
|
108
|
Toba FA, Akashi H, Arrecubieta C, Lowy FD. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg 2010; 141:1259-64. [PMID: 20709333 DOI: 10.1016/j.jtcvs.2010.07.016] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Revised: 06/22/2010] [Accepted: 07/04/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVE Infections, especially those involving drivelines, are among the most serious complications that follow ventricular assist device implantation. Staphylococci are the most common causes of these infections. Once driveline infections are established, they can remain localized or progress as an ascending infection to cause metastatic seeding of other tissue sites. Although elaboration of biofilm appears to be critical in prosthetic device infections, its role as a facilitator of staphylococcal infection and migration along the driveline and other prosthetic devices is unclear. METHODS A murine model of driveline infection was used to investigate staphylococcal migration along the driveline. A biofilm-producing strain of Staphylococcus epidermidis and a Staphylococcus aureus strain and its intercellular adhesion gene cluster (ica)-negative (biofilm-deficient) isogenic mutant were used in these studies. Bacterial density on the driveline and the underlying tissue was measured over time. Scanning electron microscopy was used to examine the morphology of S epidermidis biofilm formation as the infection progressed. RESULTS The biofilm-deficient S aureus mutant was less effective at infecting and migrating along the driveline than the wild-type strain over time. However, the ica mutation had no effect on the ability of the strain to infect underlying tissue. S aureus exhibited more rapid migration than S epidermidis. Scanning electron microscopy revealed the deposition of host matrix on the Dacron material after implantation. This was followed by elaboration of a bacterial biofilm that correlated with more rapid migration along the driveline. CONCLUSIONS Biofilm formation is a critical virulence determinant that facilitates the progression of drivelines infections.
Collapse
Affiliation(s)
- Faustino A Toba
- Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
| | | | | | | |
Collapse
|
109
|
Cadeiras M, von Bayern M, Deng MC. Managing drugs and devices in patients with permanent ventricular assist devices. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2010; 9:318-31. [PMID: 17761117 DOI: 10.1007/s11936-007-0027-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Patients will be considered for destination mechanical circulatory support device (MCSD) implantation when all other organ-saving treatment options have failed and they are not eligible for heart transplantation. Current medical evidence suggests that only for those patients who are inotrope-dependent and therefore likely have a 1-year survival probability without MCSD implantation of less than 50%, MCSD intervention will add to survival and quality-of-life benefit. Suitable candidates for MCSD are those patients who have a high risk of dying from heart failure but acceptable noncardiac risk. Evaluation of patients for MCSD requires a systematic and critical review of all organ systems and of the psychosocial situation. Specifically, right ventricular function and risk of right ventricular failure should be evaluated before planning destination MCSD implantation. Treatment will focus on prompt recovery from MCSD implantation, maintaining optimal treatment for heart failure, and preventing/treating MCSD complications, including infection, bleeding, coagulopathy, right heart failure, and device dysfunction. MCSD programs should be organized as an advanced heart failure center directed by specialized heart failure cardiologists, surgeons expert at implant and management of MCSD, specialized nurses, social workers, psychologists, financial experts, and physical therapists. MCSD practice is based on a patient-centered theory, with an appropriate understanding of the respective roles of the physician and the patient during their iterative encounters in which the patient is an autonomous person making responsible personal health decisions while the health care team is providing continued expert and empathic counseling about various options, based on systematic outcomes research (eg, by participation in the Interagency Registry for Mechanically Assisted Circulatory Support - MCSD database ).
Collapse
Affiliation(s)
- Martin Cadeiras
- Cardiac Transplantation Research, Division of Cardiology, Department of Medicine, Columbia University College of Physicians & Surgeons, New York Presbyterian Hospital, PH Room 1291, 622 W. 168th Street, New York, NY 10032, USA
| | | | | |
Collapse
|
110
|
Aslam S, Hernandez M, Thornby J, Zeluff B, Darouiche RO. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010; 50:664-71. [PMID: 20113174 DOI: 10.1086/650454] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Infection is a common complication of ventricular-assist devices (VADs) and is associated with rehospitalization, thromboembolic events, VAD malfunction, delay in heart transplantation, and a high mortality rate. The objectives of this study were to investigate the frequency of fungal VAD infections and assess various risk factors and their effects on mortality as compared with bacterial VAD infections. METHODS We conducted a retrospective chart review of patients with infected VADs at a single tertiary care center. The frequency, risk factors, and outcomes of fungal versus bacterial VAD infections were compared. RESULTS Of the 300 patients who received a VAD, 108 (36%) developed VAD infection, including 85 bacterial and 23 fungal infections. Most common bacterial causes of infection were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, and Pseudomonas aeuruginosa. The most common fungal etiologic agent was Candida albicans. Only the use of total parenteral nutrition was associated with the development of a fungal VAD infection in multivariate analysis (odds ratio, 6.95; 95% confidence interval, 1.71-28.16; P=.007). Patients who experienced fungal VAD infection were less likely to be cured (17.4% vs 56.3%; P=.001) and had greater mortality (91% vs 61%; P=.006), compared with those who experienced bacterial VAD infection. CONCLUSIONS Fungi were responsible for approximately one-fifth of VAD infections and were associated with a mortality rate of 91%. Restriction of total parenteral nutrition use is essential in decreasing the rate of fungal VAD infection. Trials are needed for investigating the use of echinocandins or lipid formulations of amphotericin B for prevention and/or treatment of fungal VAD infection.
Collapse
Affiliation(s)
- Saima Aslam
- Baylor College of Medicine, Houston, Texas, USA.
| | | | | | | | | |
Collapse
|
111
|
Maeda T, Tanoue Y, Nakashima A, Tominaga R. Atypical presentation of an apical pseudoaneurysm in a patient on prolonged left ventricular mechanical support. Interact Cardiovasc Thorac Surg 2010; 10:350-1. [DOI: 10.1510/icvts.2009.220582] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
112
|
Bagdasarian NG, Malani AN, Pagani FD, Malani PN. Fungemia Associated with Left Ventricular Assist Device Support. J Card Surg 2009; 24:763-5. [DOI: 10.1111/j.1540-8191.2009.00919.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Natasha G. Bagdasarian
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, Michigan
| | - Anurag N. Malani
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, Michigan
- Saint Joseph Mercy Health System, Ann Arbor, Michigan
| | - Francis D. Pagani
- Department of Surgery, Section of Cardiothoracic Surgery, University of Michigan Health System, Ann Arbor, Michigan
| | - Preeti N. Malani
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, Michigan
- Department of Internal Medicine, Division of Geriatric Medicine, University of Michigan Health System, Ann Arbor, Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, Michigan
- Geriatric Research Education and Clinical Center (GRECC), University of Michigan Health System, Ann Arbor, Michigan
| |
Collapse
|
113
|
|
114
|
Wilson SR, Givertz MM, Stewart GC, Mudge GH. Ventricular Assist Devices. J Am Coll Cardiol 2009; 54:1647-59. [DOI: 10.1016/j.jacc.2009.06.035] [Citation(s) in RCA: 119] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2009] [Revised: 06/18/2009] [Accepted: 06/21/2009] [Indexed: 11/15/2022]
|
115
|
Abstract
Ventricular assist devices are an important therapeutic option for advanced congestive heart failure. A left ventricular assist device (LVAD) can be implanted as a bridge to transplantation or for the purpose of destination therapy. LVADs improve end-organ function and reduce morbidity and mortality in appropriately selected patients. The development of axial flow pumps has overcome many of the limitations of the first-generation pulsatile flow LVADs. However, many complications of LVAD therapy remain. Treating these complications requires an understanding of LVAD physiology. Ongoing research is directed at reducing the incidence of many of these complications and may allow for wider use of LVADs.
Collapse
Affiliation(s)
- Gabriel Sayer
- The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
| | | | | |
Collapse
|
116
|
Arrecubieta C, Toba FA, von Bayern M, Akashi H, Deng MC, Naka Y, Lowy FD. SdrF, a Staphylococcus epidermidis surface protein, contributes to the initiation of ventricular assist device driveline-related infections. PLoS Pathog 2009; 5:e1000411. [PMID: 19412528 PMCID: PMC2670519 DOI: 10.1371/journal.ppat.1000411] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2008] [Accepted: 04/02/2009] [Indexed: 11/24/2022] Open
Abstract
Staphylococcus epidermidis remains the predominant pathogen in prosthetic-device infections. Ventricular assist devices, a recently developed form of therapy for end-stage congestive heart failure, have had considerable success. However, infections, most often caused by Staphylococcus epidermidis, have limited their long-term use. The transcutaneous driveline entry site acts as a potential portal of entry for bacteria, allowing development of either localized or systemic infections. A novel in vitro binding assay using explanted drivelines obtained from patients undergoing transplantation and a heterologous lactococcal system of surface protein expression were used to identify S. epidermidis surface components involved in the pathogenesis of driveline infections. Of the four components tested, SdrF, SdrG, PIA, and GehD, SdrF was identified as the primary ligand. SdrF adherence was mediated via its B domain attaching to host collagen deposited on the surface of the driveline. Antibodies directed against SdrF reduced adherence of S. epidermidis to the drivelines. SdrF was also found to adhere with high affinity to Dacron, the hydrophobic polymeric outer surface of drivelines. Solid phase binding assays showed that SdrF was also able to adhere to other hydrophobic artificial materials such as polystyrene. A murine model of infection was developed and used to test the role of SdrF during in vivo driveline infection. SdrF alone was able to mediate bacterial adherence to implanted drivelines. Anti-SdrF antibodies reduced S. epidermidis colonization of implanted drivelines. SdrF appears to play a key role in the initiation of ventricular assist device driveline infections caused by S. epidermidis. This pluripotential adherence capacity provides a potential pathway to infection with SdrF-positive commensal staphylococci first adhering to the external Dacron-coated driveline at the transcutaneous entry site, then spreading along the collagen-coated internal portion of the driveline to establish a localized infection. This capacity may also have relevance for other prosthetic device–related infections. This study investigates the manner in which heart pumps become infected. Infections involving the driveline, the cord that connects the pump to its external power source, are a major complication of implantation of these devices. In this study, we examined why Staphylococcus epidermidis, a bacteria that is commonly found on the skin, is responsible for the majority of these infections. The ability of different surface molecules of S. epidermidis to attach to drivelines removed from patients undergoing transplantation was tested. SdrF, one of the S. epidermidis surface proteins studied, showed the highest adherence to the drivelines. This binding appeared to involve attachment of the B subunit of SdrF to collagen, a molecule that coats the driveline following implantation. SdrF also mediated attachment to the non-implanted Dacron material that is used to coat the drivelines. A mouse driveline infection model also demonstrated that SdrF was sufficient to initiate a driveline infection. Driveline infection can therefore be hypothesized to occur via: 1) skin colonization by S. epidermidis; 2) adherence of SdrF-positive S. epidermidis to the Dacron surface at the skin entry site; 3) migration of bacteria along the driveline; 4) adherence to the internal driveline via the collagen coating its surface; and 5) initiation of infection.
Collapse
Affiliation(s)
- Carlos Arrecubieta
- Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America
| | - Faustino A. Toba
- Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America
| | - Manuel von Bayern
- Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America
| | - Hirokazu Akashi
- Department of Surgery, New York Presbyterian Hospital, Columbia University, New York, New York, United States of America
| | - Mario C. Deng
- Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America
| | - Yoshifumi Naka
- Department of Surgery, New York Presbyterian Hospital, Columbia University, New York, New York, United States of America
| | - Franklin D. Lowy
- Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America
- Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America
- * E-mail:
| |
Collapse
|
117
|
Exposed Left Ventricular Assist Device Salvage Using the Components Separation Technique. Plast Reconstr Surg 2008; 122:225e-227e. [DOI: 10.1097/prs.0b013e31818d22d2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
118
|
Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 2008; 198:571-5. [PMID: 18613794 DOI: 10.1086/590210] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Staphylococcus aureus is a leading cause of ventricular assist device-related infections. This study evaluated the protective effect against S. aureus infection of active and passive immunization that targeted 3 proteins involved in bacterial attachment to a murine intra-aortic polyurethane patch. Active immunization of mice with a combination of the A domains of clumping factor A (ClfA), fibronectin-binding protein A (FnBPA) and fibronectin-binding protein B or passive immunization with monoclonal antibodies against ClfA and FnBPA resulted in a higher level of protection than that obtained by vaccination with either protein or antibody alone. The combination of antibodies or protein antigens appears to provide enhanced protection against prosthetic-device infection.
Collapse
Affiliation(s)
- Carlos Arrecubieta
- Divisions of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
| | | | | | | | | | | |
Collapse
|
119
|
Rizzieri AG, Verheijde JL, Rady MY, McGregor JL. Ethical challenges with the left ventricular assist device as a destination therapy. Philos Ethics Humanit Med 2008; 3:20. [PMID: 18694496 PMCID: PMC2527574 DOI: 10.1186/1747-5341-3-20] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 08/11/2008] [Indexed: 05/26/2023] Open
Abstract
The left ventricular assist device was originally designed to be surgically implanted as a bridge to transplantation for patients with chronic end-stage heart failure. On the basis of the REMATCH trial, the US Food and Drug Administration and the US Centers for Medicare & Medicaid Services approved permanent implantation of the left ventricular assist device as a destination therapy in Medicare beneficiaries who are not candidates for heart transplantation. The use of the left ventricular assist device as a destination therapy raises certain ethical challenges. Left ventricular assist devices can prolong the survival of average recipients compared with optimal medical management of chronic end-stage heart failure. However, the overall quality of life can be adversely affected in some recipients because of serious infections, neurologic complications, and device malfunction. Left ventricular assist devices alter end-of-life trajectories. The caregivers of recipients may experience significant burden (e.g., poor physical health, depression, anxiety, and posttraumatic stress disorder) from destination therapy with left ventricular assist devices. There are also social and financial ramifications for recipients and their families. We advocate early utilization of a palliative care approach and outline prerequisite conditions so that consenting for the use of a left ventricular assist device as a destination therapy is a well informed process. These conditions include: (1) direct participation of a multidisciplinary care team, including palliative care specialists, (2) a concise plan of care for anticipated device-related complications, (3) careful surveillance and counseling for caregiver burden, (4) advance-care planning for anticipated end-of-life trajectories and timing of device deactivation, and (5) a plan to address the long-term financial burden on patients, families, and caregivers.Short-term mechanical circulatory devices (e.g. percutaneous cardiopulmonary bypass, percutaneous ventricular assist devices, etc.) can be initiated in emergency situations as a bridge to permanent implantation of ventricular assist devices in chronic end-stage heart failure. In the absence of first-person (patient) consent, presumed consent or surrogate consent should be used cautiously for the initiation of short-term mechanical circulatory devices in emergency situations as a bridge to permanent implantation of left ventricular assist devices. Future clinical studies of destination therapy with left ventricular assist devices should include measures of recipients' quality of end-of-life care and caregivers' burden.
Collapse
Affiliation(s)
- Aaron G Rizzieri
- Department of Philosophy, Arizona State University, 300 East University Drive, Tempe, Arizona, 85287, USA
| | - Joseph L Verheijde
- Department of Physical Medicine and Rehabilitation, Mayo Clinic Hospital, Mayo Clinic Arizona, 5777 East Mayo Boulevard, Phoenix, Arizona, 85054, USA
- Bioethics, Policy, and Law Program, Arizona State University, 300 East University Drive, Tempe, Arizona, 85287, USA
| | - Mohamed Y Rady
- Department of Critical Care Medicine, Mayo Clinic Hospital, Mayo Clinic Arizona, 5777 East Mayo Boulevard, Phoenix, Arizona, 85054, USA
| | - Joan L McGregor
- Bioethics, Policy, and Law Program, Arizona State University, 300 East University Drive, Tempe, Arizona, 85287, USA
| |
Collapse
|
120
|
Eshelman AK, Mason S, Nemeh H, Williams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev 2008; 14:21-8. [DOI: 10.1007/s10741-007-9075-5] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2007] [Accepted: 11/28/2007] [Indexed: 01/08/2023]
|
121
|
Markl M, Benk C, Klausmann D, Stalder AF, Frydrychowicz A, Hennig J, Beyersdorf F. Three-dimensional magnetic resonance flow analysis in a ventricular assist device. J Thorac Cardiovasc Surg 2007; 134:1471-6. [PMID: 18023667 DOI: 10.1016/j.jtcvs.2007.05.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2007] [Revised: 04/13/2007] [Accepted: 05/02/2007] [Indexed: 10/22/2022]
Abstract
OBJECTIVE The assessment of flow characteristics inside ventricular assist devices by magnetic resonance imaging techniques may provide insight into the mechanisms underlying the high rate of thromboembolic events after implantation of a ventricular assist device. Furthermore, these investigations may form the basis to optimize the device's design and its need for anticoagulation. The purpose of this study was to integrate a clinical routine ventricular assist device into a flow circuit with realistic geometric and pulsatile inflow conditions. Combination with flow-sensitive magnetic resonance imaging at 3 T permitted the detailed analysis of local and global 3-dimensional flow dynamics in a realistic environment. METHODS A commercially available ventricular assist device was integrated into a magnetic resonance-compatible flow circuit. Flow-sensitive 3-dimensional magnetic resonance imaging was performed to measure time-resolved 3-directional flow velocities in the entire device. Advanced computer-aided 3-dimensional flow visualization methods were used to derive a comprehensive picture of flow dynamics within the ventricular assist device system. RESULTS On the basis of the ventricular assist device model system, magnetic resonance imaging, and flow visualization, the first 4-dimensional functional magnetic resonance imaging analysis of flow characteristics inside an operating clinical routine ventricular assist device chamber system is reported. Detailed visualization of flow patterns and local changes in flow characteristics were successfully performed and revealed locally accelerated, vortical, and helical flow regions inside the geometry of the device. CONCLUSIONS Complex flow patterns such as vortex formation and locally accelerated flow demonstrate the potential of the presented method to further deepen the understanding of complex and regionally different flow characteristics inside ventricular assist devices.
Collapse
Affiliation(s)
- Michael Markl
- Department of Diagnostic Radiology, Medical Physics, University Hospital Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
122
|
Mattner F, Chaberny IF, Mattner L, Gastmeier P, Tessmann R, Strüber M. [Infection control measures and surveillance of patients with ventricular assist devices]. Anaesthesist 2007; 56:429-36. [PMID: 17431552 DOI: 10.1007/s00101-007-1155-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Ventricular assist devices (VAD) are a new routine therapy option for end-stage heart failure. However, the incidence of VAD-related infections varies between 20 and 188% and makes a major contribution to VAD-related morbidity. Therefore, optimised infection control policies should be applied to prevent VAD-related infections. As to date only a few studies exist investigating particular prevention measures for VAD recipients, we have tried to adapt evidence-based guidelines. In detail the following preventive measures are discussed: antibiotic prophylaxis, endocarditis prophylaxis, dressing technique for the driveline-exit site and education of patients and medical staff. A new patient-based surveillance system is proposed which reflects the different times since implantation of VADs and therefore allows a fair method for interhospital comparison.
Collapse
Affiliation(s)
- F Mattner
- Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Deutschland.
| | | | | | | | | | | |
Collapse
|
123
|
von Bayern MP, Cadeiras M, Deng MC. Destination therapy: does progress depend on left ventricular assist device development? Heart Fail Clin 2007; 3:349-67. [PMID: 17723941 DOI: 10.1016/j.hfc.2007.04.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The role of therapy using mechanical circulatory support devices has evolved rapidly over the last two decades. New developments in the field achieved smaller adverse events, but, currently, only minor improvements in survival were observed in published observational data. The authors discuss the development of mechanical circulatory support devices as a "destination therapy" option for patients who have end-stage heart failure and are ineligible for heart transplantation as it relates to left ventricular assist device development.
Collapse
|
124
|
Chumnanvej S, Wood MJ, MacGillivray TE, Melo MFV. Perioperative echocardiographic examination for ventricular assist device implantation. Anesth Analg 2007; 105:583-601. [PMID: 17717209 DOI: 10.1213/01.ane.0000278088.22952.82] [Citation(s) in RCA: 107] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Ventricular assist devices (VADs) are systems for mechanical circulatory support of the patient with severe heart failure. Perioperative transesophageal echocardiography is a major component of patient management, and important for surgical and anesthetic decision making. In this review we present the rationale and available data for a comprehensive echocardiographic assessment of patients receiving a VAD. In addition to the standard examination, device-specific pre-, intra-, and postoperative considerations are essential to the echocardiographic evaluation. These include: (a) the pre-VAD insertion examination of the heart and large vessels to exclude significant aortic regurgitation, tricuspid regurgitation, mitral stenosis, patent foramen ovale, or other cardiac abnormality that could lead to right-to-left shunt after left VAD placement, intracardiac thrombi, ventricular scars, pulmonic regurgitation, pulmonary hypertension, pulmonary embolism, and atherosclerotic disease in the ascending aorta; and to assess right ventricular function; and (b) the post-VAD insertion examination of the device and reassessment of the heart and large vessels. The examination of the device aims to confirm completeness of device and heart deairing, cannulas alignment and patency, and competency of device valves using two-dimensional, and color, continuous and pulsed wave Doppler modalities. The goal for the heart examination after implantation should be to exclude aortic regurgitation, or an uncovered right-to-left shunt; and to assess right ventricular function, left ventricular unloading, and the effect of device settings on global heart function. The variety of VAD models with different basic and operation principles requires specific echocardiographic assessment targeted to the characteristics of the implanted device.
Collapse
Affiliation(s)
- Siriluk Chumnanvej
- Department of Anesthesia and Critical Care, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
| | | | | | | |
Collapse
|
125
|
Asai T, Lee MH, Arrecubieta C, von Bayern MP, Cespedes CA, Baron HM, Cadeiras M, Sakaguchi T, Marboe CC, Naka Y, Deng MC, Lowy FD. Cellular coating of the left ventricular assist device textured polyurethane membrane reduces adhesion of Staphylococcus aureus. J Thorac Cardiovasc Surg 2007; 133:1147-53. [PMID: 17467422 DOI: 10.1016/j.jtcvs.2006.10.084] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2006] [Revised: 10/07/2006] [Accepted: 10/25/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Infections are among the most common and serious complications of ventricular assist device implantation. These infections generally occur within the first 2 months after surgery. The basis for this high incidence of infection is not well established, so a murine intravascular infection model was developed with aortic implantation of the textured polyurethane patch material currently used in HeartMate ventricular assist devices (Thoratec Corporation Pleasanton, Calif). METHODS Polyurethane patch material was placed in the wall of the mouse descending aorta. Mice were then infected with Staphylococcus aureus 1 or 14 days after implantation. In vitro adhesion studies were conducted with polyurethane membranes coated with endothelial cells and membranes coated with fibrinogen. RESULTS Mice were susceptible to infection in both dose- and time-dependent fashions. The patch material was significantly more susceptible to infection at day 1 than day 14. Immunohistologic and morphologic studies demonstrated that the CD31+ cells deposited on the membrane surface phenotypically appeared to be endothelial cells. In vitro adhesion studies of polyurethane membranes coated with endothelial cells showed them to be less susceptible to S. aureus binding than were membranes coated with fibrinogen. CONCLUSION Textured polyurethane membranes are less susceptible to infection as cellular deposition occurs. The time frame within which these membranes become populated with cellular material is consistent with the time-dependent clinical incidence of infection. Cellular coating of polyurethane may provide a strategy for reducing the risk of infection.
Collapse
Affiliation(s)
- Tomohiro Asai
- Department of Surgery, New York Presbyterian Hospital, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|